TuHURA Biosciences (HURA) 10-K 3 Sep 15 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2015	Aug. 26, 2015	Dec. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	DelMar Pharmaceuticals, Inc.
Entity Central Index Key	1,498,382
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-K
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Trading Symbol	dmpi
Entity Public Float			$ 22.8
Entity Common Stock, Shares Outstanding		39,477,556

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Current assets
Cash and cash equivalents	$ 1,754,433	$ 4,759,711
Taxes and other receivables	25,831	9,572
Prepaid expenses	245,038	$ 234,627
Deferred costs	550,119
Assets	2,575,421	$ 5,003,910
Current liabilities
Accounts payable and accrued liabilities	762,265	244,906
Related party payables	90,820	54,960
Liabilities, Current	$ 853,085	299,866
Loan payable to Valent		276,439
Stock option liability	$ 179,445	217,759
Derivative liability	1,031,004	3,329,367
Liabilities	2,063,534	$ 4,123,431
Stockholders' Equity
Preferred stock Authorized 5,000,000 shares, $0.001 par value Issued and outstanding 278,530 Series A shares at March 31, 2015 (June 30, 2014 - none)	$ 278,530
1 special voting share at March 31, 2015 (June 30, 2014 - 1)
Common stock Authorized 200,000,000 shares, $0.001 par value 39,455,931 issued at June 30, 2015 (June 20, 2014 - 35,992,343)	$ 39,456	$ 35,992
Additional paid-in capital	17,500,008	13,286,278
Warrants	6,138,426	6,200,445
Accumulated deficit	(23,465,711)	(18,663,414)
Accumulated other comprehensive income	21,178	21,178
Stockholders' equity, total	511,887	880,479
Liabilities and Equity	$ 2,575,421	$ 5,003,910

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Preferred stock, Shares authorized	5,000,000	5,000,000
Preferred stock, Par value	$ 0.001	$ 0.001
Preferred stock special voting shares issued	1	1
Common stock, Shares authorized	200,000,000	200,000,000
Common stock, Par value	$ 0.001	$ 0.001
Common stock, Shares issued	39,455,931	35,992,343
Series A Preferred Stock
Preferred Stock, Shares issued	278,530
Preferred stock, Shares outstanding	278,530

Consolidated Statement of Opera

Consolidated Statement of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Expenses
Research and development	$ 2,555,754	$ 2,119,217
General and administrative	2,168,899	3,134,409
Operating Expenses	4,724,653	5,253,626
Other loss (income)
Change in fair value of derivative liability	(179,170)	(8,300,438)
Change in fair value of derivative liability due to change in warrant terms	(23,658)	$ (111,179)
Loss on exchange of warrants	249,062
Foreign exchange loss	23,415	$ 22,581
Interest expense	2,091	8,140
Interest income	(363)	(2,078)
Other (income) loss	71,377	(8,382,974)
Net and comprehensive loss (income) for the year	$ 4,796,030	$ (3,129,348)
Basic loss (income) per share	$ 0.13	$ (0.10)
Diluted loss (income) per share	$ 0.13	$ 0
Basic weighted average number of shares	38,067,516	31,969,595
Diluted weighted average number of shares	38,067,516	39,090,331

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Deficiency) - USD ($)	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Warrants	Retained Earnings [Member]
Beginning balance at Jun. 30, 2013	$ (7,712,924)	$ 31,150	$ 7,585,810	$ 21,178		$ 6,441,700	$ (21,792,762)
Beginning balance (Shares) at Jun. 30, 2013		31,150,009
Exercise of placement agent warrants (note 7)		$ 124	239,476			$ (239,600)
Exercise of placement agent warrants (note 7) (shares)		123,810
Exercise of CA$0.50 unit warrants (note 7)	$ 259,315	$ 241	259,074
Exercise of CA$0.50 unit warrants (note 7) (shares)		241,000
Exercise of Investor Warrants net of cash issue costs (note 7)	2,477,090	$ 3,929	2,473,161
Exercise of Investor Warrants net of cash issue costs (note 7) (shares)		3,929,524
Reclassification of derivative liability to equity upon exercise of Investor Warrants (note 6)	1,110,548		1,110,548
Exercise of CA$0,50 broker warrants (note 7)	$ 3,660	$ 8	4,751			$ (1,099)
Exercise of CA$0,50 broker warrants (note 7) (shares)		8,000
Expiration of broker warrants (note 7)			556			$ (556)
Shares issued for services (note 7)	$ 633,500	$ 540	632,960
Shares issued for services (note 7) (shares)		540,000
Stock-based compensation (note 7)	979,942		$ 979,942
Income\Loss for the period	3,129,348						$ 3,129,348
Ending balance at Jun. 30, 2014	880,479	$ 35,992	$ 13,286,278	$ 21,178		$ 6,200,445	$ (18,663,414)
Ending balance (Shares) at Jun. 30, 2014		35,992,343
Exercise of Investor Warrants net of cash issue costs (note 7)	1,266,177	$ 1,986	1,264,191
Exercise of Investor Warrants net of cash issue costs (note 7) (shares)		1,986,074
Reclassification of derivative liability to equity upon exercise of Investor Warrants (note 6)	391,422		391,422
Shares issued upon the exchange of warrants (note 6)	977,897	$ 946	976,951
Shares issued upon the exchange of warrants (note 6) (shares)		945,514
Reclassification of derivative liability to equity upon amendment of warrant terms (note 6)	975,278		975,278
Reclassification of stock option liability (note 7)	38,038		38,038
Exercise of CA$0,50 broker warrants (note 7)	$ 138,000	$ 345	187,034			$ (49,379)
Exercise of CA$0,50 broker warrants (note 7) (shares)		345,000
Expiration of broker warrants (note 7)			$ 12,640			$ (12,640)
Issuance of Series A preferred stock (note 4)	$ 278,530				$ 278,530
Shares issued for services (note 7)	181,187	$ 187	$ 181,000
Shares issued for services (note 7) (shares)		187,000
Stock-based compensation (note 7)	187,176		$ 187,176
Series A preferred stock dividend (note 4)	(6,267)						$ (6,267)
Income\Loss for the period	(4,796,030)						(4,796,030)
Ending balance at Jun. 30, 2015	$ 511,887	$ 39,456	$ 17,500,008	$ 21,178	$ 278,530	$ 6,138,426	$ (23,465,711)
Ending balance (Shares) at Jun. 30, 2015		39,455,931

Consolidated Statement of Chan6

Consolidated Statement of Changes in Stockholders' Equity (Deficiency) (Parentheticals) - CA [Member] - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Exercise of unit warrants price		$ 0.50
Exercise of broker warrants price	$ 0.50	$ 0.50

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
(Loss) income for the period	$ (4,796,030)	$ 3,129,348
Items not affecting cash
Accrued interest	2,091	8,140
Change in fair value of derivative liability	(179,170)	(8,300,438)
Change in fair value of derivative liability due change in warrant terms	(23,658)	$ (111,179)
Loss on exchange of warrants	$ 249,062
Warrants issued for services		$ 124,020
Stock-based compensation	$ 368,087	1,519,944
Net income (loss) after adjustments of non-cash items	(4,379,618)	(3,630,165)
Changes in non-cash working capital
Taxes and other receivables	(16,259)	7,322
Prepaid expenses	(10,411)	(13,365)
Accounts payable and accrued liabilities	517,359	(186,321)
Related party payables	35,860	(181,502)
Total changes in non-cash working capital	526,549	(373,866)
Net cash flows from operating activities	(3,853,069)	(4,004,031)
Cash flows from financing activities
Net proceeds from the exercise of warrants	1,404,177	$ 2,480,750
Deferred costs	(550,119)
Series A preferred stock dividend	(6,267)
Net cash flows from financing activities	847,791	$ 2,480,750
Increase (decrease) in cash and cash equivalents	(3,005,278)	(1,523,281)
Cash and cash equivalents - beginning of year	4,759,711	6,282,992
Cash and cash equivalents - end of year	1,754,433	$ 4,759,711
Supplementary information
Issuance of preferred shares for the settlement of the loan payable with Valent (note 4)	278,530
Reclassification of derivative liability to equity upon the exercise of Investor Warrants (note 6)	391,422	$ 1,110,548
Reclassification of derivative liability to equity upon the exchange of Investor Warrants (note 6)	728,835
Reclassification of derivative liability to equity upon the amendment of Dividend Warrants (note 6)	975,278
Reclassification of stock option liability to equity upon the forfeiture of stock options (note 6)	$ 38,038
Exercise of CA$0.50 warrants for no additional consideration (note 6)		$ 259,315

Consolidated Statement of Cash8

Consolidated Statement of Cash Flows (Parentheticals)	12 Months Ended
	Jun. 30, 2014CAD / shares
Statement of Cash Flows [Abstract]
Warrants exercise price	CAD 0.50

Going Concern, Nature of Operat

Going Concern, Nature of Operations, and Corporate History	12 Months Ended
	Jun. 30, 2015
Going concern, nature of operations, and corporate history [Abstract]
Going concern, nature of operations, and corporate history	1 Going concern, nature of operations, and corporate history Going concern These financial statements have been prepared on a going concern basis which assumes that DelMar Pharmaceuticals, Inc. (the “Company”) will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the year ended June 30, 2015, the Company reported a loss of $4,796,030, negative cash flow from operations of $3,853,069 (2014 - $4,004,031) and an accumulated deficit of $23,465,711 at that date. As at June 30, 2015, the Company has cash and cash equivalents on hand of $1,754,433 and a working capital balance of $1,722,336. The Company has not begun to generate revenues from its product candidate and the Company does not have the prospect of achieving revenues in the near future. The Company will require additional funding to maintain its research and development projects and for general operations. These circumstances indicate the existence of a material uncertainty that casts substantial doubt as to the ability of the Company to meet its obligations as they come due. Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Subsequent to June 30, 2015 the Company received net proceeds of approximately $1.9 million from a registered-direct offering of common stock and common stock purchase warrants (note 12). Management plans to secure the necessary additional financing through the issue of new equity and/or the entering into of strategic partnership arrangements. Nevertheless, there is no assurance that these initiatives will be successful. These financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material. Nature of operations The Company is a clinical stage drug development company with a focus on the treatment of cancer. We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme (“GBM”), the most common and aggressive form of brain cancer. We have also acquired certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (“CML”) and lung cancer. In order to accelerate our development timelines and reduce technical risk, we leverage existing clinical and commercial data from a wide range of sources. We plan to seek marketing partnerships in China in order to potentially generate future royalty revenue. The address of the Company’s administrative offices is Suite 720 - 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 with clinical operations located at 3485 Edison Way, Suite R, Menlo Park, California, 94025. Corporate history The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only Inc. On January 25, 2013 (the “Closing Date”), the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“DelMar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of DelMar (BC). Upon completion of the Exchange Agreement, DelMar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). As a result of the shareholders of DelMar (BC) having a controlling interest in the Company subsequent to the Reverse Acquisition, for accounting purposes the transaction is a capital transaction with DelMar (BC) being the accounting acquirer even though the legal acquirer is Berry. No goodwill was recorded with respect to the transaction as it did not constitute a business combination. For accounting purposes, the transaction is reflected as a recapitalization of DelMar (BC) and consideration for the Reverse Acquisition was deemed to be the fair value of the shares that were issued by DelMar (BC) to acquire the net liabilities of Berry on January 25, 2013. Therefore, the historic financial statements of DelMar (BC) are presented as the comparative balances for the periods prior to the Reverse Acquisition. DelMar Pharmaceuticals, Inc. is the parent company of DelMar (BC), a British Columbia, Canada corporation incorporated on April 6, 2010, which is a clinical stage company with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. References to the Company refer to the Company and its wholly-owned subsidiaries, DelMar (BC), Callco and Exchangeco.

Change in Fiscal Year End

Change in Fiscal Year End	12 Months Ended
	Jun. 30, 2015
Change in Fiscal Year End [Abstract]
Change in fiscal year end	2 Change in fiscal year end On July 21, 2014, the Board of Directors of the Company approved a change in the Company’s fiscal year end from December 31 to June 30. As a result of this change, the Company has prepared consolidated financial statements for the years ended June 30, 2015 and 2014. References to any of the Company’s 2013 or earlier fiscal years mean the fiscal year ending December 31 of that calendar year.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Significant accounting policies	3 Significant accounting policies Basis of presentation The financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”) and are presented in United States dollars. The Company’s functional currency is the United States dollar. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all periods presented. Consolidation The consolidated financial statements include the accounts of Del Mar (BC), Callco, and Exchangeco as of and for the period ended June 30, 2015. Inter-company balances and transactions have been eliminated on consolidation. Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements. Cash and cash equivalents Cash and cash equivalents consist of cash on deposit and highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less. Cash and cash equivalents are held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations and comprehensive loss. Foreign currency translation The functional currency of the Company at June 30, 2015 is the United States dollar. Transactions that are denominated in a foreign currency are re-measured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently re-measured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations and comprehensive loss. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations and comprehensive loss for the period. Current and future income taxes The Company follows the liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current period. Income taxes are accounted for using the asset and liability method of accounting. Future income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Future income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on future income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of future income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided. Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and • Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities, related party payables and derivative liability. The carrying values of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. Derivative liability The Company accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a simulated probability valuation model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of similar life sciences companies. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. a) Fair value of derivative liability The Company has the following liabilities under the fair value hierarchy: June 30, 2015 Liability Level 1 Level 2 Level 3 Derivative liability - 1,031,004 - June 30, 2014 Liability Level 1 Level 2 Level 3 Derivative liability - 3,329,367 - Intangible assets Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. Once the technology has achieved commercialization, patent costs will be deferred and amortized over the remaining life of the related patent. Research and development costs (including clinical trial expenses) Research and development expenses include payroll, employee benefits, stock-based compensation expense, and other headcount-related expenses associated with product research and development. Research and development expenses also include third-party development and clinical trial expenses noted bel0w. Such costs related to product research and development are included in research and development expense until the point that technological feasibility is reached, which for our drug candidate, is generally shortly before the drug is approved by the relevant food and drug administration. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated life of the product. Clinical trial expenses are a component of research and development costs and include fees paid to contract research organizations, investigators and other service providers who conduct specific research for product development activities on behalf of the Company. The amount of clinical trial expenses recognized in a period related to service agreements is based on estimates of the work performed on an accrual basis. These estimates are based on patient enrollment, services provided and goods delivered, contractual terms and experience with similar contracts. The Company monitors these factors to the extent possible and adjusts our estimates accordingly. Prepaid expenses or accrued liabilities are adjusted if payments to service providers differ from estimates of the amount of service completed in a given period. Research and development costs are expensed in the period incurred. At June 30, 2015 and 2014 all research and development costs have been expensed. Shares for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument granted (see notes 6 and 7 for assumptions). Stock options The Company accounts for these awards under Accounting Standards Codification (“ASC”) 718, “Compensation - Stock Compensation” (“ASC 718”). ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period for awards expected to vest. Compensation expense for unvested options to non-employees is revalued at each period end and is being amortized over the vesting period of the options. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company’s share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. These variables are projected based on the Company’s historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including type of awards granted, employee class, and historical experience. Actual results and future estimates may differ substantially from current estimates. Comprehensive income In accordance with ASC 220, “Comprehensive Income” (“ASC 220”) all components of comprehensive income, including net loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and other comprehensive (income) loss, including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income. No taxes were recorded on items of other comprehensive income. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the year ended June 30, 2015 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants and stock options are anti-dilutive. At June 30, 2015, potential common shares of 17,067,870 (2014 – 21,919,699) related to outstanding warrants and stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive. For the year ended June 30, 2014 diluted income per share has also been presented. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding stock options and warrants. Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single operating segment being the research and development of cancer indications, and operates in one geographic area, being North America. All of the Company’s assets are located in either Canada or the United States. Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Accounting Standards Update (“ASU”) 2014-15 - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern The objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity's ability to continue as a going concern within one year after the issuance date of an entity’s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after December 15, 2016 (December 31, 2016 for calendar year-end entities). Earlier application is permitted. The Company is currently assessing this standard for its impact on future reporting periods. ASU 2014-10 Topic 915, Development Stage Entities The objective of the guidance is to reduce cost and complexity in the financial reporting system by eliminating inception-to-date information from the financial statements of development stage entities. The new standard eliminates the concept of a development stage entity (“DSE”) from US GAAP. Therefore, the current incremental reporting requirements for a DSE, including inception-to-date information, will no longer apply. This standard is effective for annual reporting periods beginning after December 15, 2014. The Company has elected to early adopt this guidance effective with its June 30, 2014 consolidated financial statements. ASU 3013-05 Topic 830, Accounting for Cumulative Translation Adjustments The standard amends cumulative translation adjustment derecognition guidance in particular when (i) an entity ceases to have a controlling financial interest in certain subsidiaries or groups of assets within a foreign entity, or (ii) there is a loss of a controlling financial interest in a foreign entity or a step acquisition involving an equity method investment that is a foreign entity. This is effective for public entities for years, and interim periods within those years, beginning after December 15, 2013. ASU 2013-11 Topic 740, Accounting for Cumulative Translation Adjustments The standard amends guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This is effective for public entities for years, and interim periods within those years, beginning after December 15, 2013.

Valent Technologies LLC Agreeme

Valent Technologies LLC Agreement	12 Months Ended
	Jun. 30, 2015
Valent Technologies LLC agreements [Abstract]
Valent Technologies LLC agreements	4 Valent Technologies LLC agreements On September 12, 2010 the Company entered into a Patent Assignment Agreement (the “Assignment Agreement”) with Valent to acquire patents and the prototype drug product related to VAL-083. In accordance with the Assignment Agreement the Company paid $250,000 to acquire the prototype drug product. In addition, under certain circumstances Valent agreed to assign, convey and transfer to the Company all its right, title and interest in and to the patents in exchange for share purchase warrants. The Company will then be responsible for the further development and commercialization of VAL-083. Valent retained an option to reacquire certain intellectual property until a Financing Transaction is completed by the Company. Under the Assignment Agreement, a ‘Financing Transaction’ is defined as a cumulative equity or debt financing(s), or a merger, acquisition, amalgamation, reverse takeover or other combination, or any combination of the foregoing, cumulatively totaling at least $2,000,000. In accordance with the terms of the Assignment Agreement, Valent is entitled to receive a future royalty on revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Assignment Agreement. On January 25, 2013, in connection with the Company’s Reverse Acquisition (note 1), the Company issued to Valent 1,150,000 shares of common stock, in exchange for Valent reducing certain future royalties under the Assignment Agreement. Pursuant to a loan agreement dated February 3, 2011, the Company received a loan from Valent of $250,000 for the purchase of the prototype drug product. The loan was unsecured and bears interest at 3.00% per year. The loan was originally due on demand but was converted to a five year term loan due, along with all accrued interest, on June 30, 2019. As a result, the Company has presented the full loan and accrued interest balance as a non-current liability at June 30, 2014. Pursuant to the Assignment Agreement with Valent, the Company agreed to issue warrants to Valent under certain circumstances. The financing completed by the Company that closed in February 2012 constituted a Financing Transaction under the terms of the Assignment Agreement and resulted in the Company issuing 500,000 warrants to Valent on February 1, 2012 at an exercise price of CA$0.50 per warrant (note 7). In exchange for the warrants Valent has assigned all of its right, title and interest in and to the patents for VAL-083 to the Company. The fair value of the contingent warrants of $89,432 has been recognized as an expense and a corresponding increase to additional paid-in capital in prior periods. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent. Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $278,530 (including aggregate accrued interest to September 30, 2014 of $28,530), issued to Valent by DelMar (BC), for 278,530 shares of the Company’s Series A Preferred Stock. Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the “Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock will be entitled to dividends at the rate of 3% of the Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. For the year ended June 30, 2015, the Company recorded $6,267 related to the dividend payable to Valent and $2,091 related to interest from July 1, 2014 to September 30, 2014 when the loan was exchanged for preferred stock. The dividend of $6,267 has been recorded as a direct increase in accumulated deficit while the $2,091 has been recorded as interest expense. For the year ended June 30, 2014 the Company accrued $8,140 in interest expense on its loan payable with Valent. One of the Company’s officers and directors is a principal of Valent and as result Valent is a related party to the Company (note 8).

Taxes and Other Receivables

Taxes and Other Receivables	12 Months Ended
	Jun. 30, 2015
Taxes and Other Receivables [Abstract]
Taxes and other receivables	5 Taxes and other receivables June 30, 2015 $ June 30, 2014 $ Government grants 9,820 562 Other receivables 16,011 9,010 25,831 9,572 On June 15, 2014, the Company was granted a non-repayable financial contribution from the National Research Council of Canada Industrial Research Assistance Program (“IRAP”). The Company will be reimbursed for certain research and development costs to a maximum of $155,635 (CA$194,398) in the period from June 15, 2014 through June 15, 2017. The total amount credited in the statement of operations for all IRAP grants for the year ended June 30, 2015 was $62,943 (2014 - $562).

Derivative Liability

Derivative Liability	12 Months Ended
	Jun. 30, 2015
Derivative liability [Abstract]
Derivative liability	6 Derivative liability The Company has issued common stock purchase warrants. Based on the terms of certain of these warrants the Company determined that the warrants were a derivative liability which is recognized at fair value at the date of the transaction and re-measured at fair value each reporting period with the changes in fair value recorded in the consolidated statement of operations and comprehensive loss. CA$0.50 Unit Warrants During the years ended December 31, 2012 and 2011 the Company issued a total of 5,410,000 units for services, settlement of accounts payable, and cash proceeds for an aggregate of $2,671,923 (CA$2,705,000). The proceeds from the issuance of 3,000,000 of these units were held in escrow pursuant to an exclusive option investment agreement with a strategic investor. Subsequently, the Company elected to allow the option to expire and the related units were cancelled and the funds returned from escrow to the subscriber in order for the Company to retain control over certain intellectual property and commercial rights. During the year ended June 30, 2014, 241,000 of these warrants were exercised for no additional consideration for 241,000 shares of common stock with $259,315 of the derivative liability being reclassified to equity. The warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded. On January 25, 2014, the remaining 2,169,000 of these warrants expired. Investor Warrants In connection with the Reverse Acquisition (note 1), on January 25, 2013, January 31, 2013, February 8, 2013, February 21, 2013, February 28, 2013, March 1, 2013, and March 6, 2013, the Company entered into and closed a series of subscription agreements with accredited investors (the “Investors”), pursuant to which the Company issued an aggregate of 13,125,002 units at a purchase price of $0.80 per unit, for aggregate gross proceeds of $10,500,000 (the “Private Offering”). Each unit consists of one share of common stock and one five-year warrant (the “Investor Warrants”) to purchase one share of common stock at an exercise price of $0.80. The exercise price of the Investor Warrants is subject to adjustment in the event that the Company sells common stock at a price lower than the exercise price, subject to certain exceptions. The Investor Warrants are redeemable by the Company at a price of $0.001 per Investor Warrant at any time subject to the conditions that (i) the Company’s common stock has traded for twenty (20) consecutive trading days with a closing price of at least $1.60 per share with an average trading volume of 50,000 shares per day and (ii) the underlying shares of common stock are registered. Investor warrant exercises On June 6, 2014, pursuant to an Election to Exercise Warrants agreement, the Company reduced the Investor Warrant exercise price from $0.80 to $0.65 per share for warrants to purchase 3,652,211 shares of the Company’s common stock. In accordance with the agreements, the holders of the Investor Warrants exercised the Investor Warrants for cash at the foregoing reduced exercise price. The Company received net proceeds of $2,255,240 after paying a 5% warrant agent fee of $118,697. As a result, $984,484 of the derivative liability has been reclassified to equity. In addition, during the year ended June 30, 2014, 277,313 warrants were exercised at $0.80 per warrant for 277,313 shares of common stock. The Company received proceeds of $221,850 from the exercise. As a result, $126,064 of the derivative liability has been reclassified to equity. Tender offer – Investor Warrant exercise price reduction On June 9, 2014, as amended on June 26, 2014, July 10, 2014, and July 29, 2014, the Company filed a tender offer statement with the Securities and Exchange Commission with respect to certain Investor Warrants to provide the holders thereof with the opportunity to amend and exercise their warrants, upon the terms and subject to the conditions set forth in the Company’s tender offer statement. Pursuant to the tender offer, the Company offered to amend Investor Warrants to purchase an aggregate of 9,195,478 shares of common stock (the “Offer to Amend and Exercise”). There was no minimum participation requirement with respect to the Offer to Amend and Exercise. Pursuant to the Offer to Amend and Exercise, the Investor Warrants subject to the tender offer were amended (the “Amended Warrants”) to: (i) reduce the exercise price of the Investor Warrants from $0.80 per share to $0.65 per share of common stock in cash, (ii) shorten the exercise period of the Investor Warrants so that they expire concurrently with the expiration of the Offer to Amend and Exercise at 5:00 p.m. (Pacific Time) on August 8, 2014, as may be extended by the Company in its sole discretion (“Expiration Date”), (iii) delete the price-based anti-dilution provisions contained in the Investor Warrants, (iv) restrict the ability of the holder of shares issuable upon exercise of the Amended Warrants to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any of such shares without the prior written consent of the Company for a period of time twenty (20) days after the Expiration Date (the “ Lock-Up Period ”); and (v) provide that a holder, acting alone or with others, will agree not to effect any purchases or sales of any securities of the Company in any “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, or any type of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) or similar arrangements, or sales or other transactions through non-U.S. broker dealers or foreign regulated brokers through the expiration of the Lock-Up Period. Upon the expiry of the Offer to Amend and Exercise on August 8, 2014, 762,227 Amended Warrants were exercised for net proceeds of $470,676 after payment by the Company of a 5% warrant agent fee of $24,772. As a result, 8,433,251 Investor Warrants remained outstanding under their original terms subsequent to the tender offer. In addition to the price reduction tender offer, during the year ended June 30, 2015, 1,223,847 Investor Warrants were exercised at $0.65 per share for 1,223,847 shares of common stock. The Company received proceeds of $795,501 from these exercises. As a result of all of the Investor Warrants exercised for cash at $0.65 per warrant, including the tender offer relating to the price reduction to $0.65, a total of $391,422 of the derivative liability has been reclassified to equity. All Investor Warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded. Investor Warrant exchange On December 31, 2014, the Company issued 414,889 shares of common stock in exchange for 1,244,666 Investor Warrants. The Investor Warrants that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The reclassification to equity upon the exchange was $305,112. The Company recognized a loss of $92,843 at the time of the exchange. Tender offer warrant exchange On January 8, 2015, the Company filed a tender offer statement with the Securities and Exchange Commission, and on January 23, 2015, the Company filed an amendment thereto, with respect to certain Investor Warrants to purchase common stock of the Company. The tender offer provided the holders of the Investor Warrants with the opportunity to receive one share of common stock for every three Investor Warrants tendered. The tender offer was available to all 5,964,738 Investor Warrants outstanding on January 8, 2015. To participate in the tender offer the Investor Warrant holders were required to deliver completed exchange documents to the Company, prior to the expiration of the tender offer, which was 5:00 p.m. (Pacific Time) on February 9, 2015. The tender offer expired on February 9, 2015. A total of 1,591,875 Investor Warrants were exchanged for 530,625 shares of common stock. The Investor Warrants that have been exchanged were revalued at their exchange date and then a reclassification to equity was recorded. The reclassification to equity upon the exchange was $423,723. The Company recognized a loss of $156,219 at the time of the exchange. The remaining 4,372,863 Investor Warrants outstanding at June 30, 2015 have been re-valued at June 30, 2015 using a simulated probability valuation model using the following assumptions: dividend rate - 0%, volatility – 76.6%, risk free rate – 1.14% and a term of approximately 2.5 years. All 4,372,863 Investor Warrants outstanding at June 30, 2015 have an exercise price of $0.80 at June 30, 2015. However, subsequent to June 30, 2015, the Company issued shares of common stock at $0.60 per share (note 12). As a result of the Investor Warrants being subject to adjustment in the event that the Company sells common stock at a price lower than the exercise price, subject to certain exceptions, the 4,372,863 Investor Warrants outstanding at June 30, 2015 now have an exercise price of $0.786. Dividend warrants In connection with the Reverse Acquisition (note 1), warrants that Berry issued pursuant a warrant dividend became warrants of the Company (the “Dividend Warrants”). The Dividend Warrants are exercisable at $1.25 per share until January 24, 2018. The Dividend Warrants will only be exercisable at such times as the underlying shares of common stock are registered. The Dividend Warrants will be redeemable by the Company at a price of $0.001 per Dividend Warrant at any time commencing 18 months following the date of issuance subject to the conditions that (i) the Company’s common stock has traded for twenty (20) consecutive trading days with a closing price of at least $2.50 per share and (ii) the underlying shares of common stock are registered. Subject to the conditions set forth therein, the Dividend Warrants may be redeemed by the Company upon not less than ninety (60) days nor more than ninety (90) days prior written notice. On October 31, 2014, the Company and all of its Dividend Warrant holders entered into amendments to the Dividend Warrants such that the Company’s redemption rights and certain provisions of the Dividend Warrant agreements relating to potential cash settlement of the Dividend Warrants were removed. The Dividend Warrants were revalued to the date of the amendment on October 31, 2014 which resulted in a reclassification to equity of $975,278. Warrants issued for services During the year ended December 31, 2013, the Company issued 300,000 warrants for services. The warrants were issued on September 12, 2013 and are exercisable on a cashless basis at an exercise price of $1.76 for five years. The Company has recognized $124,020 in expense in the consolidated statement of operations. The warrants have been measured at fair value at their issue date of June 30, 2015 using a simulated probability valuation model using the following assumptions: dividend rate - 0%, volatility – 76.7%, risk free rate - 1.31% and a term of approximately 3.25 years. The Company’s derivative liability is summarized as follows: June 30, June 30, Opening balance 3,329,367 12,986,827 Change in fair value of warrants (179,170 ) (8,300,438 ) Change in fair value due to change in warrant terms (23,658 ) (111,179 ) Reclassification to equity upon amendment of warrants (975,278 ) - Warrants issued for services - 124,020 Reclassification to equity upon exchange of warrants (728,835 ) - Reclassification to equity upon exercise of warrants (391,422 ) (1,369,863 ) Closing balance 1,031,004 3,329,367

Stockholders' Equity (Deficienc

Stockholders' Equity (Deficiency)	12 Months Ended
	Jun. 30, 2015
Stockholders Equity [Abstract]
Stockholders' equity	7 Stockholders’ equity (deficiency) Preferred stock Authorized 5,000,000 preferred shares, $0.001 par value Issued and outstanding Special voting shares – at June 30, 2015 and 2014 – 1 Series A shares – at June 30, 2015 – 278,530 (June 30, 2014 – none) Effective September 30, 2014 pursuant to the Valent Exchange Agreement (note 4), the Company filed the Series A Certificate of Designation with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the “Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock will be entitled dividends at the rate of 3% of the Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. In connection with the Exchange Agreement (note 1), on the Closing Date, the Company, Callco, Exchangeco and Computershare Trust Company of Canada (the “Trustee”) entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, Company issued one share of Special Voting Preferred Stock (the “Special Voting Share”) to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Share for the benefit of the holders of the shares of Exchangeco acquired as part of the Reverse Acquisition (the “Exchangeable Shares”) (other than the Company and any affiliated companies) (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Exchange Agreement and the Trust Agreement, on January 17, 2013, the Company filed a certificate of designation of Special Voting Preferred Stock (the “Special Voting Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Stock. The Special Voting Preferred Stock votes as a single class with the common stock and is entitled to a number of votes equal to the number of Exchangeable Shares of Exchangeco outstanding as of the applicable record date (i) that are not owned by the Company or any affiliated companies and (ii) as to which the holder has received voting instructions from the holders of such Exchangeable Shares in accordance with the Trust Agreement. The Special Voting Preferred Stock is not entitled to receive any dividends or to receive any assets of the Company upon any liquidation, and is not convertible into common stock of the Company. The voting rights of the Special Voting Preferred Stock will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Stock will be automatically cancelled at such time as the share of Special Voting Preferred Stock has no votes attached to it. Common stock Authorized 200,000,000 common shares, $0.001 par value Issued and outstanding at June 30, 2015 – 39,455,931 (2014 – 35,992,343). The issued and outstanding common shares at June 30, 2015 include 4,256,042 (2014 - 7,044,583) shares of common stock on an as-exchanged basis with respect to the Exchangeable Shares (note 1). a) Shared issued for services During the year ended June 30, 2015, the Company issued 187,000 (June 30, 2014 – 540,000) shares of common stock for services resulting in the recognition of $181,187 (June 30, 2014 - $633,500) in expense. The total shares for services expense for the year ended June 30, 2015 of $181,187 (June 30, 2014 - $633,500) in addition to the stock option expense for the period of $186,900 (June 30, 2014 - $886,444) and warrants issued for services of $nil (2014 - $124,020) results in a total share-based payment expense of $368,087 for the year ended June 30, 2015 (June 30, 2014 - $1,643,964). This total expense has been recognized as to $36,284 (June 30, 2014 - $404,177) and $331,803 (June 30 2014 - $1,239,787) for research and development, and general and administrative respectively for the year ended June 30, 2015. Stock options On February 1, 2012, the Company’s Board of Directors approved its stock option plan (the “Plan”). Under the Plan the number of common shares that will be reserved for issuance to officers, directors, employees and consultants under the Plan will not exceed 7.5% of the share capital of the Company on a fully diluted basis. The requisite service period of the options ranges from six months to three years and also has a range of six months to three years contractual term. In the event of the sale of 66 2/3% of the equity securities of the Company where equity securities include shares, warrants, stock options, and any convertible securities of the Company, any options not yet granted under the Plan shall be deemed granted to the principal founders of the Company on a pro-rata basis in accordance with their ownership of the Company on a fully-diluted basis immediately prior to the closing of such a sale. The following table sets forth the options outstanding under the Plan as of June 30, 2015: Number of stock options outstanding Weighted average exercise price Balance – June 30, 2013 1,140,000 0.78 Granted 2,100,000 1.06 Forfeited (52,786 ) 0.87 Balance – June 30, 2014 3,187,214 0.96 Granted 600,000 0.88 Cancelled (120,000 ) 1.05 Forfeited (72,214 ) 0.53 Balance - June 30, 2015 3,595,000 0.94 The following table summarizes stock options currently outstanding and exercisable at June 30, 2015: Exercise $ Number Outstanding at June 30, 2015 Weighted average remaining contractual life (years) Weighted average exercise price $ Number exercisable at June 30, 2015 Exercise price $ 0.40 825,000 6,63 0.40 825,000 0.40 0.74 180,000 9.60 0.74 56,389 0.74 0.80 120,000 9.75 0.80 30,000 0.80 1.00 300,000 4.25 1.00 50,000 1.00 1.05 1,870,000 8.13 1.05 1,611,250 1.05 1.54 180,000 7.75 1.54 180,000 1.54 2.30 120,000 7.92 2.30 120,000 2.30 3,595,000 0.94 2,872,639 0.94 Included in the number of stock options outstanding are 825,000 stock options granted at an exercise price of CA$ $0.50. The exercise prices for these stock options shown in the above table have been converted to $0.40 US$ using the period ending closing exchange rate. Certain stock options have been granted to non-employees and will be revalued at each reporting date until they have fully vested. The stock options have been valued using a Black-Scholes pricing model using the following assumptions: June 30, 2015 June 30, 2014 Dividend rate 0 % 0 % Volatility 67% to 85% 73% to 76% Risk-free rate 1.00% to 1.25% 1.25 % Term - years 0.5 to 2.5 0.5 to 2.5 The Company has recognized the following amounts as stock-based compensation expense for the periods noted: Years ended June 30, 2015 $ 2014 $ Research and development 36,284 358,177 General and administrative 150,616 528,267 186,900 886,444 Of the total stock option expense of $186,900 (2014 - $886,443) for the year ended June 30, 2015, $225,214 (2014 - $979,942) has been recognized as additional paid in capital and $38,314 (2014 – a reduction of $93,498) has been recognized as reduction to stock option liability. The aggregate intrinsic value of stock options outstanding at June 30, 2015 was $203,528 (2014 - $372,454) and the aggregate intrinsic value of stock options exercisable at June 30, 2015 was also $203,528 (2014 - $336,853). As of June 30, 2015 there was $57,335 in unrecognized compensation expense that will be recognized over the next year. No stock options granted under the Plan have been exercised to June 30 2015. Upon the exercise of stock options new shares will be issued. A summary of status of the Company’s unvested stock options as of June 30, 2015 under all plans is presented below: Number of options Weighted average exercise price $ Weighted average grant date fair value $ Unvested at June 30, 2013 420,083 1.06 0.61 Granted 2,100,000 1.06 0.58 Vested (1,731,616 ) 1.06 0.58 Forfeited (52,786 ) 0.87 0.49 Unvested at June 30, 2014 735,681 0.98 0.54 Granted 600,000 0.88 0.32 Vested (421,106 ) 0.94 0.48 Forfeited (72,214 ) 0.53 0.36 Cancelled (120,000 ) 1.05 0.57 Unvested at June 30, 2015 722,361 0.95 0.41 The aggregate intrinsic value of unvested stock options at June 30, 2015 was $0 (2014 - $35,601). The unvested stock options have a remaining weighted average contractual term of 7.24 years. Warrants Number of warrants Amount $ Balance – June 30, 2013 6,200,000 6,441,700 Warrants exercised on a cashless basis (i) (200,000 ) (239,600 ) Expiry of broker warrants (ii) (5,000 ) (556 ) Exercise of broker warrants (iii) (8,000 ) (1,099 ) Balance – June 30, 2014 5,987,000 6,200,445 Expiry of broker warrants (ii) (92,000 ) (12,640 ) Exercise of broker warrants (iv) (345,000 ) (49,379 ) Balance - June 30, 2015 5,550,000 6,138,426 i) During the year ended June 30, 2014, 200,000 warrants issued for placement agent services (the “Placement Agent Warrants”) were exercised on a cashless basis for 123,810 shares of common stock. ii) The Company has issued broker warrants as finder’s fees in relation to the issuance of certain securities. All of the warrants were issued on March 1, 2012 and have an exercise price of CA$0.50 per warrant. Of the total, 5,000 expired during the year ended June 30, 2014 and 92,000 expired during the year ended June 30, 2015. iii) During the year ended June 30, 2014, 8,000 broker warrants were exercised for proceeds of $3,660 (CA$4,000). iv) The Company has issued 345,000 warrants for investor relations services. The warrants were issued on February 1, 2012 and vested in 12 equal installments over a 12-month period commencing on March 1, 2012. The warrants have an exercise price of CA$0.50 per warrant. The 345,000 warrants were exercised during the year ended June 30, 2015 for cash proceeds of $138,000 (CA$ 172,500). Certain of the Company’s warrants have been recognized as a derivative liability (note 6). The following table summarizes all of the Company’s outstanding warrants as of June 30, 2015: Description Number Issued for patents (i) 500,000 Investor Warrants (ii) 4,372,863 Dividend Warrants (iii) 3,250,007 Placement Agent (iv) 5,050,000 Issued for services (v) 300,000 Closing balance - June 30, 2015 13,472,870 i) The Company issued 500,000 warrants to Valent (note 4). The warrants have an exercise price of CA$0.50 per warrant and expire February 1, 2017. ii) The Investor Warrants were issued as part of the Company’s $0.80 unit offering. They were issued in tranches on January 25, 2013, January 31, 2013, February 8, 2013, February 21, 2013, February 28, 2013, March 1, 2013, and March 6, 2013 respectively. Of the initial number issued of 13,125,002, 277,313 have been exercised at $0.80, 5,638,285 have been exercised at $0.65, and 2,836,541 have been exchanged on a three for one basis for 945,514 shares of common stock. As a result of the Company issuing common shares at $0.60 per share subsequent to June 30, 2015, the exercise price of all remaining 4,372,863 Investor Warrants has been reduced to $0.786 per Investor Warrant (note 12). iii) The Dividend Warrants are exercisable at $1.25 per share until January 24, 2018. iv) The Placement Agent Warrants are exercisable at $0.80 per share until March 6, 2018 but can be exercised on a cashless basis. The Placement Agent Warrants were all issued on March 6, 2013. The exercise price of the Placement Agent Warrants is subject to adjustment in the event that the Company sells common stock at a price lower than the exercise price, subject to certain exceptions. As a result of the Company issuing common shares at $0.60 per share subsequent to June 30, 2015, the exercise price of all remaining 5,050,000 Placement Investor Warrants has been reduced to $0.786 per share (note 12). v) The warrants are exercisable on a cashless basis at a price of $1.76 per share until September 12, 2018.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related party transactions	8 Related party transactions During the year ended June 30, 2015 Effective September 30, 2014, the Company entered into and closed an agreement with Valent to exchange its loan with Valent for 278,530 shares of preferred stock of the Company (note 4). Pursuant to consulting agreements with the Company’s officers the Company recognized a total of $505,000 in compensation expense for the year ended June 30, 2015. Included in accounts payable at June 30, 2015 is an aggregate amount of $90,820 owed to the Company’s officers and directors for fees and expenses. The Company pays related party payables incurred for fees and expenses under normal commercial terms. The Company recognized $119,417 in directors’ fees during the year ended June 30, 2015. During the year ended June 30, 2014 Pursuant to consulting agreements with the Company’s officers the Company recognized a total of $425,845 in compensation expense for the year ended June 30, 2014. The Company recognized $77,833 in directors’ fees during the year ended June 30, 2014.

Current and Future Income Taxes

Current and Future Income Taxes	12 Months Ended
	Jun. 30, 2015
Current and Future Income Taxes [Abstract]
Current and future income taxes	9 Current and future income taxes The Company has the following non-capital losses available to reduce taxable income of future years: Expiry date $ 2029 65,450 2030 1,043,923 2031 1,132,631 2033 3,913,138 2034 5,417,455 2035 2,843,797 Significant components of the Company’s future tax assets are shown below: June 30, 2015 $ June 30, 2014 $ Non-capital losses carried forward 4,342,685 2,686,530 Financing costs 10,565 7,737 Scientific research and development 183,913 144,235 4,537,163 2,838,502 Valuation allowance (4,537,163 ) (2,838,502 ) Net future tax assets - - The income tax benefit of these tax attributes has not been recorded in these consolidated financial statements because of the uncertainty of their recovery. The Company’s effective income tax rate differs from the statutory income tax rate of 34% (2014 - 34%). The differences arise from the following items: June 30, 2015 $ June 30, 2014 $ Tax recovery at statutory income tax rates (1,630,650 ) (989,430 ) Permanent differences (49,820 ) 110,113 Effect of rate differentials between jurisdictions 327,485 149,219 Other (4,783 ) (8,713 ) Change in valuation allowance 1,357,768 738,811 - -

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Jun. 30, 2015
Commitments and contingencies [Abstract]
Commitments and contingencies	10 Commitments and contingencies Office lease The Company currently rents its offices pursuant to a one-year lease that commenced on May 27, 2015 at a rate of $3,082 (CA$3,850) per month. During the year ended June 30, 2015, the Company recorded $29,429 as rent expense (2014 - $23,850).

Financial Risk Management

Financial Risk Management	12 Months Ended
	Jun. 30, 2015
Financial Risk Management [Abstract]
Financial risk management	11 Financial risk management Market risk Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company’s income or valuation of its financial instruments. The Company is exposed to financial risk related to fluctuation of foreign exchange rates. Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the United Sates dollar, primarily general and administrative expenses incurred in Canadian dollars. The Company believes that the results of operations, financial position and cash flows would be affected by a sudden change in foreign exchange rates, but would not impair or enhance its ability to pay its Canadian dollar accounts payable. The Company manages foreign exchange risk by converting its US$ to CA$ as needed. The Company maintains the majority of its cash in US$. As at June 30, 2015, Canadian dollar denominated accounts payable and accrued liabilities exposure in US$ totaled $217,423. a) Foreign exchange risk Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. If foreign exchange rates were to fluctuate within +/-10% of the closing rate at year-end, the maximum exposure is $21,742. Balances in foreign currencies at June 30, 2015 and 2014 are as follows: June 30, 2015 balances CA$ June 30, 2014 balances CA$ Trade payables 201,169 136,825 Cash 88,205 65,513 b) Interest rate risk The Company is subject to interest rate risk on its cash and cash equivalents and believes that the results of operations, financial position and cash flows would not be significantly affected by a sudden change in market interest rates relative to the investment interest rates due to the short-term nature of the investments. As at June 30, 2015, cash and cash equivalents held in Canadian dollar accounts or short-term investments were $70,618. The Company’s cash balance currently earns interest at standard bank rates. If interest rates were to fluctuate within +/-10% of the closing rate at year end the impact of the Company’s interest bearing accounts will be not be significant. The only financial instruments that expose the Company to interest rate risk are its cash and cash equivalents. Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet cash flow requirements associated with financial instruments. The Company continues to manage its liquidity risk based on the outflows experienced for the period ended June 30, 2015 and is undertaking efforts to conserve cash resources wherever possible. The maximum exposure of the Company’s liquidity risk is $853,084 at June 30, 2015. Credit risk Credit risk arises from cash and cash equivalents, deposits with banks and financial institutions, as well as outstanding receivables. The Company limits its exposure to credit risk, with respect to cash and cash equivalents, by placing them with high quality credit financial institutions. The Company’s cash equivalents consist primarily of operating funds with commercial banks. Of the amounts with financial institutions on deposit, the following table summarizes the amounts at risk should the financial institutions with which the deposits are held cease trading: The maximum exposure of the Company’s credit risk is $25,831 at June 30, 2015. Cash and cash equivalents $ Insured amount $ Non-insured amount $ 1,754,433 70,618 1,683,815 Concentration of credit risk Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places its cash and cash equivalents in accredited financial institutions and therefore the Company’s management believes these funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent events	12 Subsequent events Issuance of common shares and warrants was declared effective by the Securities and Exchange Commission. Pursuant to the Offering, the Company issued 4,277,667 shares of common stock at $0.60 per share and 4,277,667 warrants (the “Offering Warrants”) to purchase shares of common stock at $0.001 per warrant for total gross proceeds of $2,566,660. The Offering Warrants are exercisable at $0.75 per share for a period of five years until they expire on July 31, 2020. The Company engaged certain placement agents for the sale of a portion of the shares and Offering Warrants. Under the Company’s engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the “Agent Warrants”) up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the Offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of $80,575 and issued 56,345 Agent Warrants. The Agent Warrants are exercisable at a per share price equal to $0.75 during the five-year period commencing six months from the effective date of the Offering, which period shall not extend further than five years from the effective date of the Offering. Therefore, all Agent Warrants expire on July 15, 2020. In addition to the cash commission of $80,575 the Company also incurred additional issue and closing costs of approximately $565,000 (including costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of approximately $1,921,085. Warrants for services Subsequent to June 30, 2015, the Company issued 60,000 warrants to purchase common stock for services. These warrants vest in tranches of 20,000 warrants each on November 30, 2015, December 31, 2015, and January 31, 2016 and are exercisable commencing January 1, 2016 at $0.75 until they expire on July 15, 2020. Stock options

Significant Accounting Polici21

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”) and are presented in United States dollars. The Company’s functional currency is the United States dollar. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all periods presented.
Consolidation	Consolidation The consolidated financial statements include the accounts of Del Mar (BC), Callco, and Exchangeco as of and for the period ended June 30, 2015. Inter-company balances and transactions have been eliminated on consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash on deposit and highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less. Cash and cash equivalents are held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations and comprehensive loss.
Foreign currency translation	Foreign currency translation The functional currency of the Company at June 30, 2015 is the United States dollar. Transactions that are denominated in a foreign currency are re-measured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently re-measured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations and comprehensive loss. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations and comprehensive loss for the period.
Current and future income taxes	Current and future income taxes The Company follows the liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current period. Income taxes are accounted for using the asset and liability method of accounting. Future income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Future income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on future income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of future income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.
Financial instruments	Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and • Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities, related party payables and derivative liability. The carrying values of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. Derivative liability The Company accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a simulated probability valuation model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of similar life sciences companies. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. a) Fair value of derivative liability The Company has the following liabilities under the fair value hierarchy: June 30, 2015 Liability Level 1 Level 2 Level 3 Derivative liability - 1,031,004 - June 30, 2014 Liability Level 1 Level 2 Level 3 Derivative liability - 3,329,367 -
Intangible assets	Intangible assets Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. Once the technology has achieved commercialization, patent costs will be deferred and amortized over the remaining life of the related patent.
Research and development costs (including clinical trial expenses)	Research and development costs (including clinical trial expenses) Research and development expenses include payroll, employee benefits, stock-based compensation expense, and other headcount-related expenses associated with product research and development. Research and development expenses also include third-party development and clinical trial expenses noted bel0w. Such costs related to product research and development are included in research and development expense until the point that technological feasibility is reached, which for our drug candidate, is generally shortly before the drug is approved by the relevant food and drug administration. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated life of the product. Clinical trial expenses are a component of research and development costs and include fees paid to contract research organizations, investigators and other service providers who conduct specific research for product development activities on behalf of the Company. The amount of clinical trial expenses recognized in a period related to service agreements is based on estimates of the work performed on an accrual basis. These estimates are based on patient enrollment, services provided and goods delivered, contractual terms and experience with similar contracts. The Company monitors these factors to the extent possible and adjusts our estimates accordingly. Prepaid expenses or accrued liabilities are adjusted if payments to service providers differ from estimates of the amount of service completed in a given period. Research and development costs are expensed in the period incurred. At June 30, 2015 and 2014 all research and development costs have been expensed.
Shares for services	Shares for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument granted (see notes 6 and 7 for assumptions).
Stock options	Stock options The Company accounts for these awards under Accounting Standards Codification (“ASC”) 718, “Compensation - Stock Compensation” (“ASC 718”). ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period for awards expected to vest. Compensation expense for unvested options to non-employees is revalued at each period end and is being amortized over the vesting period of the options. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company’s share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. These variables are projected based on the Company’s historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including type of awards granted, employee class, and historical experience. Actual results and future estimates may differ substantially from current estimates.
Comprehensive income	Comprehensive income In accordance with ASC 220, “Comprehensive Income” (“ASC 220”) all components of comprehensive income, including net loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and other comprehensive (income) loss, including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income. No taxes were recorded on items of other comprehensive income.
Loss per share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the year ended June 30, 2015 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants and stock options are anti-dilutive. At June 30, 2015, potential common shares of 17,067,870 (2014 – 21,919,699) related to outstanding warrants and stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive. For the year ended June 30, 2014 diluted income per share has also been presented. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding stock options and warrants.
Segment information	Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single operating segment being the research and development of cancer indications, and operates in one geographic area, being North America. All of the Company’s assets are located in either Canada or the United States.
Recent accounting pronouncements	Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Accounting Standards Update (“ASU”) 2014-15 - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern The objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity's ability to continue as a going concern within one year after the issuance date of an entity’s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after December 15, 2016 (December 31, 2016 for calendar year-end entities). Earlier application is permitted. The Company is currently assessing this standard for its impact on future reporting periods. ASU 2014-10 Topic 915, Development Stage Entities The objective of the guidance is to reduce cost and complexity in the financial reporting system by eliminating inception-to-date information from the financial statements of development stage entities. The new standard eliminates the concept of a development stage entity (“DSE”) from US GAAP. Therefore, the current incremental reporting requirements for a DSE, including inception-to-date information, will no longer apply. This standard is effective for annual reporting periods beginning after December 15, 2014. The Company has elected to early adopt this guidance effective with its June 30, 2014 consolidated financial statements. ASU 3013-05 Topic 830, Accounting for Cumulative Translation Adjustments The standard amends cumulative translation adjustment derecognition guidance in particular when (i) an entity ceases to have a controlling financial interest in certain subsidiaries or groups of assets within a foreign entity, or (ii) there is a loss of a controlling financial interest in a foreign entity or a step acquisition involving an equity method investment that is a foreign entity. This is effective for public entities for years, and interim periods within those years, beginning after December 15, 2013. ASU 2013-11 Topic 740, Accounting for Cumulative Translation Adjustments The standard amends guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This is effective for public entities for years, and interim periods within those years, beginning after December 15, 2013.

Significant Accounting Polici22

Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2015
Significant Accounting Policies [Abstract]
Schedule of derivative liabilities under the fair value hierarchy	June 30, 2015 Liability Level 1 Level 2 Level 3 Derivative liability - 1,031,004 - June 30, 2014 Liability Level 1 Level 2 Level 3 Derivative liability - 3,329,367 -

Taxes and Other Receivables (Ta

Taxes and Other Receivables (Tables)	12 Months Ended
	Jun. 30, 2015
Taxes and Other Receivables [Abstract]
Schedule of taxes and other receivables	June 30, 2015 $ June 30, 2014 $ Government grants 9,820 562 Other receivables 16,011 9,010 25,831 9,572

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Jun. 30, 2015
Derivative liability [Abstract]
Shedule of derivative liabilities	June 30, June 30, Opening balance 3,329,367 12,986,827 Change in fair value of warrants (179,170 ) (8,300,438 ) Change in fair value due to change in warrant terms (23,658 ) (111,179 ) Reclassification to equity upon amendment of warrants (975,278 ) - Warrants issued for services - 124,020 Reclassification to equity upon exchange of warrants (728,835 ) - Reclassification to equity upon exercise of warrants (391,422 ) (1,369,863 ) Closing balance 1,031,004 3,329,367

Stockholders' Equity (Deficie25

Stockholders' Equity (Deficiency) (Tables)	12 Months Ended
	Jun. 30, 2015
Stockholders Equity [Abstract]
Schedule of options outstanding under the plan	Number of stock options outstanding Weighted average exercise price Balance – June 30, 2013 1,140,000 0.78 Granted 2,100,000 1.06 Forfeited (52,786 ) 0.87 Balance – June 30, 2014 3,187,214 0.96 Granted 600,000 0.88 Cancelled (120,000 ) 1.05 Forfeited (72,214 ) 0.53 Balance - June 30, 2015 3,595,000 0.94
Schedule of stock options currently outstanding and exercisable	Exercise $ Number Outstanding at June 30, 2015 Weighted average remaining contractual life (years) Weighted average exercise price $ Number exercisable at June 30, 2015 Exercise price $ 0.40 825,000 6,63 0.40 825,000 0.40 0.74 180,000 9.60 0.74 56,389 0.74 0.80 120,000 9.75 0.80 30,000 0.80 1.00 300,000 4.25 1.00 50,000 1.00 1.05 1,870,000 8.13 1.05 1,611,250 1.05 1.54 180,000 7.75 1.54 180,000 1.54 2.30 120,000 7.92 2.30 120,000 2.30 3,595,000 0.94 2,872,639 0.94
Schedule of stock options valuation assumptions using a Black-Scholes pricing model	June 30, 2015 June 30, 2014 Dividend rate 0 % 0 % Volatility 67% to 85% 73% to 76% Risk-free rate 1.00% to 1.25% 1.25 % Term - years 0.5 to 2.5 0.5 to 2.5
Schedule of stock-based compensation expense	Years ended June 30, 2015 $ 2014 $ Research and development 36,284 358,177 General and administrative 150,616 528,267 186,900 886,444
Schedule of unvested stock options	Number of options Weighted average exercise price $ Weighted average grant date fair value $ Unvested at June 30, 2013 420,083 1.06 0.61 Granted 2,100,000 1.06 0.58 Vested (1,731,616 ) 1.06 0.58 Forfeited (52,786 ) 0.87 0.49 Unvested at June 30, 2014 735,681 0.98 0.54 Granted 600,000 0.88 0.32 Vested (421,106 ) 0.94 0.48 Forfeited (72,214 ) 0.53 0.36 Cancelled (120,000 ) 1.05 0.57 Unvested at June 30, 2015 722,361 0.95 0.41
Schedule of warrants	Number of warrants Amount $ Balance – June 30, 2013 6,200,000 6,441,700 Warrants exercised on a cashless basis (i) (200,000 ) (239,600 ) Expiry of broker warrants (ii) (5,000 ) (556 ) Exercise of broker warrants (iii) (8,000 ) (1,099 ) Balance – June 30, 2014 5,987,000 6,200,445 Expiry of broker warrants (ii) (92,000 ) (12,640 ) Exercise of broker warrants (iv) (345,000 ) (49,379 ) Balance - June 30, 2015 5,550,000 6,138,426 i) During the year ended June 30, 2014, 200,000 warrants issued for placement agent services (the “Placement Agent Warrants”) were exercised on a cashless basis for 123,810 shares of common stock. ii) The Company has issued broker warrants as finder’s fees in relation to the issuance of certain securities. All of the warrants were issued on March 1, 2012 and have an exercise price of CA$0.50 per warrant. Of the total, 5,000 expired during the year ended June 30, 2014 and 92,000 expired during the year ended June 30, 2015. iii) During the year ended June 30, 2014, 8,000 broker warrants were exercised for proceeds of $3,660 (CA$4,000). iv) The Company has issued 345,000 warrants for investor relations services. The warrants were issued on February 1, 2012 and vested in 12 equal installments over a 12-month period commencing on March 1, 2012. The warrants have an exercise price of CA$0.50 per warrant. The 345,000 warrants were exercised during the year ended June 30, 2015 for cash proceeds of $138,000 (CA$ 172,500).
Schedule of outstanding warrants	Description Number Issued for patents (i) 500,000 Investor Warrants (ii) 4,372,863 Dividend Warrants (iii) 3,250,007 Placement Agent (iv) 5,050,000 Issued for services (v) 300,000 Closing balance - June 30, 2015 13,472,870 i) The Company issued 500,000 warrants to Valent (note 4). The warrants have an exercise price of CA$0.50 per warrant and expire February 1, 2017. ii) The Investor Warrants were issued as part of the Company’s $0.80 unit offering. They were issued in tranches on January 25, 2013, January 31, 2013, February 8, 2013, February 21, 2013, February 28, 2013, March 1, 2013, and March 6, 2013 respectively. Of the initial number issued of 13,125,002, 277,313 have been exercised at $0.80, 5,638,285 have been exercised at $0.65, and 2,836,541 have been exchanged on a three for one basis for 945,514 shares of common stock. As a result of the Company issuing common shares at $0.60 per share subsequent to June 30, 2015, the exercise price of all remaining 4,372,863 Investor Warrants has been reduced to $0.786 per Investor Warrant (note 12). iii) The Dividend Warrants are exercisable at $1.25 per share until January 24, 2018. iv) The Placement Agent Warrants are exercisable at $0.80 per share until March 6, 2018 but can be exercised on a cashless basis. The Placement Agent Warrants were all issued on March 6, 2013. The exercise price of the Placement Agent Warrants is subject to adjustment in the event that the Company sells common stock at a price lower than the exercise price, subject to certain exceptions. As a result of the Company issuing common shares at $0.60 per share subsequent to June 30, 2015, the exercise price of all remaining 5,050,000 Placement Investor Warrants has been reduced to $0.786 per share (note 12). v) The warrants are exercisable on a cashless basis at a price of $1.76 per share until September 12, 2018.

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
	Jun. 30, 2015
Financial instruments [Abstract]
Schedule of derivative liabilities under the fair value hierarchy	March 31, 2015 Liability Level 1 Level 2 Level 3 Derivative liability - - 1,487,137 June 30, 2014 Liability Level 1 Level 2 Level 3 Derivative liability - - 3,329,367

Current and Future Income Tax27

Current and Future Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2015
Current and Future Income Taxes [Abstract]
Schedule of taxable income	Expiry date $ 2029 65,450 2030 1,043,923 2031 1,132,631 2033 3,913,138 2034 5,417,455 2035 2,843,797
Components of future tax assets	June 30, 2015 $ June 30, 2014 $ Non-capital losses carried forward 4,342,685 2,686,530 Financing costs 10,565 7,737 Scientific research and development 183,913 144,235 4,537,163 2,838,502 Valuation allowance (4,537,163 ) (2,838,502 ) Net future tax assets - -
Schedule of difference between income tax rate and statutory income tax rate	June 30, 2015 $ June 30, 2014 $ Tax recovery at statutory income tax rates (1,630,650 ) (989,430 ) Permanent differences (49,820 ) 110,113 Effect of rate differentials between jurisdictions 327,485 149,219 Other (4,783 ) (8,713 ) Change in valuation allowance 1,357,768 738,811 - -

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Jun. 30, 2015
Financial Risk Management [Abstract]
Schedule of balances in foreign currency	June 30, 2015 balances CA$ June 30, 2014 balances CA$ Trade payables 201,169 136,825 Cash 88,205 65,513
Fair value of off-balance sheet risks	Cash and cash equivalents $ Insured amount $ Non-insured amount $ 1,754,433 70,618 1,683,815

Going Concern, Nature of Oper29

Going Concern, Nature of Operations, and Corporate History (Details)	12 Months Ended
	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)shares	Jun. 30, 2013USD ($)shares
Related Party Transaction [Line Items]
Net and comprehensive loss (income) for the period | $	$ 4,796,030	$ (3,129,348)
Negative cash flow from operations | $	(3,853,069)	(4,004,031)
Accumulated deficit | $	(23,465,711)	(18,663,414)
Cash and cash equivalents | $	1,754,433	$ 4,759,711	$ 6,282,992
Additional paid in capital | $	1,722,336
Net proceeds from exercise of warrants | $	$ 1,404,177
Number of warrants exercised	2,331,074
Net proceeds amount | $	$ 1,900,000
Common stock, Shares issued	39,455,931	35,992,343
Common stock, Shares outstanding	39,455,931	35,992,343
Outstanding warrants	5,550,000	5,987,000	6,200,000
Outstanding options	1,020,000
Common stock outstanding shares, Percentage	80.1
U.S. Holders [Member]
Related Party Transaction [Line Items]
Common stock, Shares issued	4,340,417
Common stock, Shares outstanding	4,340,417
Canadian Holders [Member]
Related Party Transaction [Line Items]
Common stock, Shares issued	8,729,583
Common stock, Shares outstanding	8,729,583
Former Shareholders [Member]
Related Party Transaction [Line Items]
Common stock, Shares issued	13,070,000

Significant Accounting Polici30

Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Level 1 [Member]
Liability
Derivative liability
Level 2 [Member]
Liability
Derivative liability	$ 1,031,004	$ 3,329,367
Level 3 [Member]
Liability
Derivative liability

Significant Accounting Polici31

Significant Accounting Policies (Details Textual) - shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Stock options [Member] | Warrant [Member]
Significant Accounting Policies (Textual)
Antidilutive securities excluded from computation of earnings per share	17,067,870	21,919,699

Valent Technologies LLC Agree32

Valent Technologies LLC Agreement (Details)	Feb. 01, 2012USD ($)shares	Feb. 03, 2011USD ($)	Sep. 12, 2010USD ($)	Sep. 30, 2014USD ($)$ / sharesshares	Jan. 25, 2013shares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares	Feb. 01, 2012CAD / shares
Valent Technologies Llc Agreement (Textual)
Preferred Stock, par value (in dollars per share) | $ / shares						$ 0.001	$ 0.001
Interest expense						$ (2,091)	$ (8,140)
Dividends payable						$ 6,267
Series A Preferred Stock [Member]
Valent Technologies Llc Agreement (Textual)
Preferred stock, shares issued | shares						278,530
Valent Technologies, LLC [Member]
Valent Technologies Llc Agreement (Textual)
Number of warrants issued | shares						500,000
Loan payable				$ 278,530
Aggregate accrued interest				$ 28,530
Preferred stock, shares issued | shares				278,530
Accrued dividend payable						$ 6,267
Loans payable to accured interest						$ 2,091
Valent Technologies, LLC [Member] | Series A Preferred Stock [Member]
Valent Technologies Llc Agreement (Textual)
Preferred stock, shares issued | shares				278,530
Preferred Stock, par value (in dollars per share) | $ / shares				$ 1
Preferred Stock, dividend rate percentage				3.00%
DelMar Pharmaceuticals, Inc
Valent Technologies Llc Agreement (Textual)
Issuance of common shares to Valent for future royalty reduction | shares					1,150,000
Loan Agreement [Member] | Valent Technologies, LLC [Member]
Valent Technologies Llc Agreement (Textual)
Loan amount		$ 250,000
Unsecured loan interest bearing rate		3.00%
Term of unsecured loan		5 years
Due date of unsecured loan		Jun. 30, 2019
Loan Agreement [Member] | Valent Technologies, LLC [Member] | Warrant [Member]
Valent Technologies Llc Agreement (Textual)
Number of warrants issued | shares	500,000
Exercise price of warrants (in Canadian dollars per warrant) | CAD / shares								CAD 0.50
Fair value of the contingent warrants	$ 89,432
Assignment Agreement [Member]
Valent Technologies Llc Agreement (Textual)
Consideration paid to acquire patent and prototype of drug product			$ 250,000
Assignment Agreement [Member] | Valent Technologies, LLC [Member]
Valent Technologies Llc Agreement (Textual)
Least amount of financing transaction			$ 2,000,000

Taxes and Other Receivables (De

Taxes and Other Receivables (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Taxes and Other Receivables [Abstract]
Government grants	$ 9,820	$ 562
Other receivables	16,011	9,010
Total Taxes and other receivables	$ 25,831	$ 9,572

Taxes and Other Receivables (34

Taxes and Other Receivables (Details Textual)	12 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2015CAD	Jun. 30, 2014USD ($)
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Research and development expense	$ (2,555,754)		$ (2,119,217)
Total amount credited	62,943		$ 562
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Research and development expense	$ 155,635	CAD 194,398

Derivative Liability (Details)

Derivative Liability (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Schedule Of Derivative Liabilities [Roll Forward]
Opening balance	$ 3,329,367	$ 12,986,827
Change in fair value of warrants	(179,170)	(8,300,438)
Change in fair value due to change in warrant terms	(23,658)	$ (111,179)
Reclassification to equity upon amendment of warrants	$ 975,278
Warrants issued for services		$ 124,020
Reclassification to equity upon exchange of warrants	$ 728,835
Reclassification to equity upon exercise of warrants	(391,422)	$ (1,369,863)
Closing balance	$ 1,031,004	$ 3,329,367

Derivative Liability (Details T

Derivative Liability (Details Textual)	Feb. 09, 2015USD ($)shares	Aug. 08, 2014USD ($)shares	Jun. 06, 2014USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares	Oct. 31, 2014USD ($)	Jun. 30, 2015USD ($)WarrantsUnit$ / shares$ / Warrantshares	Jun. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2013$ / sharesshares	Dec. 31, 2012USD ($)unitsshares	Dec. 31, 2012CADunitsshares	Dec. 31, 2011USD ($)unitsshares	Dec. 31, 2011CADunitsshares	Jan. 08, 2015shares	Jun. 09, 2014shares	Jan. 25, 2014shares
Derivative Liability (Textual)
Exercise of CA$0.50 unit warrants							$ 259,315
Reclassification of derivative liability to equity upon exercise of Investor Warrants (note 8)						$ 391,422	1,110,548
Number of warrants of exercised | shares						2,836,541
Net proceeds from the exercise of warrants						$ 1,404,177	$ 2,480,750
Reclassification of derivative liability to equity upon the exchange of Investor Warrants (note 6)						728,835
Reclassification of derivative liability to equity upon the amendment of Dividend Warrants (note 6)						975,278
Loss on exchange of warrants						$ (249,062)
Warrants issued for services							$ 124,020
Proceeds from issuance of shares | shares									3,000,000	3,000,000	3,000,000	3,000,000
Number of units issued for services in settlement of accounts payable | units									5,410,000	5,410,000	5,410,000	5,410,000
Cash proceeds for units issued for services in settlement of accounts payable									$ 2,671,923	CAD 2,705,000	$ 2,671,923	CAD 2,705,000
Number of warrants expired | shares															2,169,000
Common Stock [Member]
Derivative Liability (Textual)
Exercise of CA$0.50 unit warrants							$ 241
Exercise of CA$0.50 unit warrants, shares | shares							241,000
Reclassification of derivative liability to equity upon exercise of Investor Warrants (note 8)
Reclassification of derivative liability to equity upon the amendment of Dividend Warrants (note 6)
Investor Warrants [Member]
Derivative Liability (Textual)
Common stock shares issued on exercise of warrants | shares							277,313
Number of warrants issued | shares							277,313
Reclassification of derivative liability to equity upon exercise of Investor Warrants (note 8)							$ 126,064
Number of warrants outstanding | shares						8,433,251								9,195,478
Exercise Price | $ / shares						$ 0.786	$ 0.80
Net proceeds from the exercise of warrants							$ 221,850
Number of units issued | WarrantsUnit						13,125,002
Exercise of CA $0.50 unit warrants | $ / shares						$ 0.80
Proceeds of units issued						$ 10,500,000
Warrant description						Each unit consists of one share of common stock and one five-year warrant (the "Investor Warrants") to purchase one share of common stock at an exercise price of $0.80.
Term of warrants						5 years
Warrants, redemption price per share | $ / Warrant						0.001
Investor warrant, Description						(i) The Company's common stock has traded for twenty (20) consecutive trading days with a closing price of at least $1.60 per share with an average trading volume of 50,000 shares per day and (ii) the underlying shares of common stock are registered.
Investor Warrant Exercises [Member]
Derivative Liability (Textual)
Common stock shares issued on exercise of warrants | shares			3,652,211			1,223,847
Reclassification of derivative liability to equity upon exercise of Investor Warrants (note 8)			$ 984,484			$ 391,422
Number of warrants of exercised | shares						1,223,847
Exercise Price | $ / shares						$ 0.65
Agent fee of warrants			$ 118,697
Percentage of agent fee of warrant			5.00%
Net proceeds from the exercise of warrants			$ 2,255,240			$ 795,501
Investor Warrant Exercises [Member] | Maximum [Member]
Derivative Liability (Textual)
Exercise Price | $ / shares			$ 0.80
Investor Warrant Exercises [Member] | Minimum [Member]
Derivative Liability (Textual)
Exercise Price | $ / shares			$ 0.65
Investor Warrant Exchange [Member]
Derivative Liability (Textual)
Common stock shares issued on exercise of warrants | shares	1,591,875			1,244,666
Number of warrants issued | shares				414,889
Reclassification of derivative liability to equity upon exercise of Investor Warrants (note 8)	$ 423,723			$ 305,112
Number of warrants outstanding | shares						4,372,863							5,964,738
Exercise Price | $ / shares						$ 0.80
Loss on exchange of warrants	$ 156,219			$ 92,843
Warrants shares issued on exchanged of common stock | shares	530,625
Common stock price per share | $ / shares						0.60
Dividend Warrants [Member]
Derivative Liability (Textual)
Dividend warrants exercise price | $ / shares						$ 1.25
Reclassification of derivative liability to equity upon the amendment of Dividend Warrants (note 6)					$ 975,278
Investor warrant, Description						The Dividend Warrants will only be exercisable at such times as the underlying shares of common stock are registered. The Dividend Warrants will be redeemable by the Company at a price of $0.001 per Dividend Warrant at any time commencing 18 months following the date of issuance subject to the conditions that (i) the Company's common stock has traded for twenty (20) consecutive trading days with a closing price of at least $2.50 per share and (ii) the underlying shares of common stock are registered. Subject to the conditions set forth therein, the Dividend Warrants may be redeemed by the Company upon not less than ninety (60) days nor more than ninety (90) days prior written notice.
Warrants Issued for Services [Member]
Derivative Liability (Textual)
Number of warrants issued | shares						345,000		300,000
Exercise Price | $ / shares								$ 1.76
Term of warrants								5 years
Amended Warrants [Member]
Derivative Liability (Textual)
Number of warrants of exercised | shares		762,227
Warrants exercisable description						(i) reduce the exercise price of the Investor Warrants from $0.80 per share to $0.65 per share of common stock in cash, (ii) shorten the exercise period of the Investor Warrants so that they expire concurrently with the expiration of the Offer to Amend and Exercise at 5:00 p.m. (Pacific Time) on August 8, 2014, as may be extended by the Company in its sole discretion ("Expiration Date"), (iii) delete the price-based anti-dilution provisions contained in the Investor Warrants, (iv) restrict the ability of the holder of shares issuable upon exercise of the Amended Warrants to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any of such shares without the prior written consent of the Company for a period of time twenty (20) days after the Expiration Date (the " Lock-Up Period ")
Agent fee of warrants		$ 24,772
Percentage of agent fee of warrant		5.00%
Net proceeds from the exercise of warrants		$ 470,676

Derivative Liability (Details37

Derivative Liability (Details Textual 1) - 12 months ended Jun. 30, 2015	Total
Warrants Issued for Services [Member]
Derivative Liability (Textual)
Fair value assumptions dividend rate	0.00%
Fair value assumptions volatility rate	76.70%
Fair value assumptions risk free rate	1.31%
Fair value assumptions expected term	3 years 3 months
Investor Warrant Exchange [Member]
Derivative Liability (Textual)
Fair value assumptions dividend rate	0.00%
Fair value assumptions volatility rate	76.60%
Fair value assumptions risk free rate	1.14%
Fair value assumptions expected term	2 years 6 months

Stockholders' Equity (Deficie38

Stockholders' Equity (Deficiency) (Details) - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Number of stock options outstanding
Ending balance	3,595,000
Weighted average exercise price
Weighted average exercise price, Ending balance	$ 0.94
Stock options [Member]
Number of stock options outstanding
Beginning balance	3,187,214	1,140,000
Granted	600,000	2,100,000
Cancelled	(120,000)
Forfeited	(72,214)	(52,786)
Ending balance	3,595,000	3,187,214
Weighted average exercise price
Weighted average exercise price, Beginning balance	$ 0.96	$ 0.78
Weighted average exercise price, Granted	0.88	1.06
Weighted average exercise price, Cancelled	1.05
Weighted average exercise price, Forfeited	0.53	0.87
Weighted average exercise price, Ending balance	$ 0.94	$ 0.96

Stockholders' Equity (Deficie39

Stockholders' Equity (Deficiency) (Details 1) - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	3,595,000
Weighted average exercise price	$ 0.94
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	3,595,000	3,187,214	1,140,000
Weighted average exercise price	$ 0.94	$ 0.96	$ 0.78
Number of stock options exercisable	2,872,639
Exercise price	$ 0.94
Stock options [Member] | 0.40 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.40
Number of stock options outstanding	825,000
Weighted average remaining contractual life (years)	6 years 7 months 17 days
Weighted average exercise price	$ 0.40
Number of stock options exercisable	825,000
Exercise price	$ 0.40
Stock options [Member] | 0.74 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.74
Number of stock options outstanding	180,000
Weighted average remaining contractual life (years)	9 years 7 months 6 days
Weighted average exercise price	$ 0.74
Number of stock options exercisable	56,389
Exercise price	$ 0.74
Stock options [Member] | 0.80 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.80
Number of stock options outstanding	120,000
Weighted average remaining contractual life (years)	9 years 9 months
Weighted average exercise price	$ 0.80
Number of stock options exercisable	30,000
Exercise price	$ 0.80
Stock options [Member] | 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 1
Number of stock options outstanding	300,000
Weighted average remaining contractual life (years)	4 years 3 months
Weighted average exercise price	$ 1
Number of stock options exercisable	50,000
Exercise price	$ 1
Stock options [Member] | 1.05 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 1.05
Number of stock options outstanding	1,870,000
Weighted average remaining contractual life (years)	8 years 1 month 17 days
Weighted average exercise price	$ 1.05
Number of stock options exercisable	1,611,250
Exercise price	$ 1.05
Stock options [Member] | 1.54 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 1.54
Number of stock options outstanding	180,000
Weighted average remaining contractual life (years)	7 years 9 months
Weighted average exercise price	$ 1.54
Number of stock options exercisable	180,000
Exercise price	$ 1.54
Stock options [Member] | 2.30 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 2.30
Number of stock options outstanding	120,000
Weighted average remaining contractual life (years)	7 years 11 months 1 day
Weighted average exercise price	$ 2.30
Number of stock options exercisable	120,000
Exercise price	$ 2.30

Stockholders' Equity (Deficie40

Stockholders' Equity (Deficiency) (Details 2) - Stock options [Member]	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend rate	0.00%	0.00%
Risk-free rate		1.25%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	67.00%	73.00%
Risk-free rate	1.00%
Term - years	6 months	6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	85.00%	76.00%
Risk-free rate	1.25%
Term - years	2 years 6 months	2 years 6 months

Stockholders' Equity (Deficie41

Stockholders' Equity (Deficiency) (Details 3) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 186,900	$ 886,444
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	36,284	358,177
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 150,616	$ 528,267

Stockholders' Equity (Deficie42

Stockholders' Equity (Deficiency) (Details 4) - Stock options [Member] - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
outstanding options
Number of options unvested, Beginning balance	735,681	420,083
Number of options, Granted	600,000	2,100,000
Number of options, Vested	(421,106)	(1,731,616)
Number of options, Forfeited	(72,214)	(52,786)
Number of options, Cancelled	(120,000)
Number of options unvested, Ending balance	722,361	735,681
Weighted Average Exercise Price
Weighted average exercise price unvested, Beginning balance	$ 0.98	$ 1.06
Weighted average exercise price unvested, Granted	0.88	1.06
Weighted average exercise price unvested, Vested	0.94	1.06
Weighted average exercise price unvested, Forfeited	0.53	0.87
Weighted average exercise price unvested, Cancelled	1.05
Weighted average exercise price unvested, Ending balance	0.95	0.98
Weighted Average Grant Date Fair Value
Weighted average grant date fair value, unvested, Beginning balance	0.54	0.61
Weighted average grant date fair value, unvested, Granted	0.32	0.58
Weighted average grant date fair value, unvested, Vested	0.48	0.58
Weighted average grant date fair value, unvested, Forfeited	0.36	0.49
Weighted average grant date fair value, unvested, Cancelled	0.57
Weighted average grant date fair value, unvested, Ending balance	$ 0.41	$ 0.54

Stockholders' Equity (Deficie43

Stockholders' Equity (Deficiency) (Details 5) - USD ($)		12 Months Ended
		Jun. 30, 2015		Jun. 30, 2014
Number of Warrants
Beginning Balance		5,987,000		6,200,000
Ending Balance		5,550,000		5,987,000
Value of Warrants
Beginning Balance		$ 6,200,445
Ending Balance		$ 6,138,426		$ 6,200,445
Warrant [Member]
Number of Warrants
Beginning Balance		5,987,000		6,200,000
Warrants exercised on a cashless basis (i)	[1]			(200,000)
Expiry of broker warrants (ii)	[2]	(92,000)		(5,000)
Exercise of broker warrants (iii) (iv)		(345,000)	[3]	(8,000)	[4]
Ending Balance		5,550,000		5,987,000
Value of Warrants
Beginning Balance		$ 6,200,445		$ 6,441,700
Warrants exercised on a cashless basis (i)	[1]			(239,600)
Expiry of broker warrants (ii)	[2]	(12,640)		(556)
Exercise of broker warrants (iii), (iv)		(49,379)	[3]	(1,099)	[4]
Ending Balance		$ 6,138,426		$ 6,200,445
[1]	During the year ended June 30, 2014, 200,000 Placement Agent Warrants were exercised on a cashless basis for 123,810 shares of common stock.
[2]	The Company has issued broker warrants as finder's fees in relation to the issuance of certain securities. All of the warrants were issued on March 1, 2012 and have an exercise price of CA$0.50 per warrant. Of the total, 5,000 expired during the year ended June 30, 2014 and 92,000 expired during the year ended June 30, 2015.
[3]	The Company has issued 345,000 warrants for investor relations services. The warrants were issued on February 1, 2012 and vested in 12 equal installments over a 12-month period commencing on March 1, 2012. The warrants have an exercise price of CA$0.50 per warrant. The 345,000 warrants were exercised during the year ended June 30, 2015 for cash proceeds of $138,000 (CA$ 172,500).
[4]	During the year ended June 30, 2014, 8,000 broker warrants were exercised for proceeds of $3,660 (CA$4,000).

Stockholders' Equity (Deficie44

Stockholders' Equity (Deficiency) (Details 6) - shares		12 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Number of Warrants [Abstract]
Warrants outstanding		5,550,000	5,987,000	6,200,000
Warrant [Member]
Number of Warrants [Abstract]
Issued for patents (i)	[1]	500,000
Investor Warrants (ii)	[2]	4,372,863
Dividend Warrants (iii)	[3]	3,250,007
Placement Agent (iv)	[4]	5,050,000
Issued for services (v)	[5]	300,000
Warrants outstanding		13,472,870
[1]	The Company issued 500,000 warrants to Valent (note 4). The warrants have an exercise price of CA$0.50 per warrant and expire February 1, 2017.
[2]	The Investor Warrants were issued as part of the Company's $0.80 unit offering. They were issued in tranches on January 25, 2013, January 31, 2013, February 8, 2013, February 21, 2013, February 28, 2013, March 1, 2013, and March 6, 2013 respectively. Of the initial number issued of 13,125,002, 277,313 have been exercised at $0.80, 5,638,285 have been exercised at $0.65, and 2,836,541 have been exchanged on a three for one basis for 945,514 shares of common stock. As a result of the Company issuing common shares at $0.60 per share subsequent to June 30, 2015, the exercise price of all remaining 4,372,863 Investor Warrants has been reduced to $0.786 per Investor Warrant (note 12).
[3]	The Dividend Warrants are exercisable at $1.25 per warrant until January 24, 2018.
[4]	The Placement Agent Warrants are exercisable at $0.80 per warrant until March 6, 2018 but can be exercised on a cashless basis. The Placement Agent Warrants were all issued on March 6, 2013
[5]	The warrants are exercisable on a cashless basis at a price of $1.76 per warrant until September 12, 2018.

Stockholders' Equity (Deficie45

Stockholders' Equity (Deficiency) (Detail Textuals) - Related Party [Domain] - Entity [Domain] - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Stockholders Equity Note [Line Items]
Preferred stock, Par value	$ 0.001	$ 0.001
Preferred stock, Shares authorized	5,000,000	5,000,000
Preferred stock special voting shares issued	1	1
Common stock, Shares authorized	200,000,000	200,000,000
Common stock, Par value	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	39,455,931	35,992,343
Common stock, Shares outstanding	39,455,931	35,992,343
Stock issued and outstanding on exchanged basis	4,256,042	7,044,583
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued	278,530
Preferred stock, Shares outstanding	278,530
Exchange Agreement | Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, Par value	$ 1
Voting and Exchange Trust Agreement
Stockholders Equity Note [Line Items]
Preferred stock special voting shares issued	1	1

Stockholders' Equity (Deficie46

Stockholders' Equity (Deficiency) (Detail Textuals 1)	Jul. 15, 2015$ / sharesshares	Jan. 31, 2016$ / shares	Dec. 31, 2014shares	Jun. 30, 2015USD ($)WarrantsUnitInstallments$ / sharesshares	Jun. 30, 2015CADWarrantsUnitInstallmentsCAD / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares	Jun. 30, 2014CADCAD / sharesshares	Dec. 31, 2013shares	Jun. 30, 2013shares
Stockholders Equity Notes [Textual]
Stock option liability | $				$ 179,445		$ 217,759
Shares issued for services | $				$ 181,187		$ 633,500
Warrants outstanding				5,550,000		5,987,000			6,200,000
Stock-based compensation expense | $				$ 186,900		$ 886,444
Warrants issued for services | $						124,020
Stock-based compensation | $				$ 368,087		$ 1,519,944
Net proceeds from exercise of warrants | $				$ 1,404,177
Warrants exercise price | CAD / shares							CAD 0.50
Number of warrants of exercised				2,836,541
Number of stock options outstanding				3,595,000
Subsequent Event [Member]
Stockholders Equity Notes [Textual]
Warrants outstanding	4,372,863
Warrants exercise price | $ / shares	$ 0.786
Valent Technologies, LLC [Member]
Stockholders Equity Notes [Textual]
Exercise price | CAD / shares					CAD 0.50
Number of warrants issued				500,000	500,000
Warrants expiration date				Feb. 1, 2017	Feb. 1, 2017
Stock options [Member]
Stockholders Equity Notes [Textual]
Stock options granted				600,000	600,000	2,100,000	2,100,000
Exercise price | $ / shares				$ 0.88		$ 1.06
Aggregate intrinsic value of stock options outstanding | $				$ 203,528		$ 372,454
Aggregate intrinsic value of stock options exercisable | $				203,528		336,853
Unrecognized compensation expense | $				57,335
Rrecognized as stock option liability | $				38,314		93,498
Stock-based compensation expense | $				$ 186,900		886,443
Threshold percentage of share capital on fully diluted basis for common stock authorized to issue				7.50%	7.50%
Percentage of equity securities deemed granted to principle founders of entity on pro rata basis as per ownership				66 2/3	66 2/3
Stock option recognized as additional paid in capital | $				$ 225,214		979,942
Aggregate intrinsic value of unvested stock options | $				$ 0		$ 35,601
Weighted average contractual term				7 years 2 months 27 days	7 years 2 months 27 days
Number of stock options outstanding				3,595,000		3,187,214			1,140,000
Stock options [Member] | 0.40 [Member]
Stockholders Equity Notes [Textual]
Unit offering price | CAD / shares					CAD 0.50
Number of stock options outstanding				825,000
Research and Development Expense [Member]
Stockholders Equity Notes [Textual]
Stock-based compensation expense | $				$ 36,284		$ 358,177
Stock-based compensation | $				36,284		404,177
General and Administrative Expense [Member]
Stockholders Equity Notes [Textual]
Stock-based compensation expense | $				150,616		528,267
Stock-based compensation | $				$ 331,803		$ 1,239,787
Common Stock [Member]
Stockholders Equity Notes [Textual]
Shares issued for services, shares				187,000	187,000	540,000	540,000
Shares issued for services | $				$ 187		$ 540
Shares issued upon the exchange of warrants				945,514	945,514
Warrants Issued for Services [Member]
Stockholders Equity Notes [Textual]
Exercise price | CAD / shares					CAD 0.50
Number of warrants issued				345,000	345,000			300,000
Net proceeds from exercise of warrants				$ 138,000	CAD 172,500
Number of installments for vesting of warrants | Installments				12	12
Vesting period of warrant				12 months	12 months
Warrants Issued for Services [Member] | Subsequent Event [Member]
Stockholders Equity Notes [Textual]
Number of warrants issued				60,000	60,000
Warrants exercise price | $ / shares		$ 0.75
Warrants expiration date		Jul. 15, 2020
Investor Warrant Exercises [Member]
Stockholders Equity Notes [Textual]
Number of warrants of exercised				1,223,847
Investor Warrant Exchange [Member]
Stockholders Equity Notes [Textual]
Number of warrants issued			414,889
Placement Agent Warrants [Member]
Stockholders Equity Notes [Textual]
Number of warrants exercisable				200,000	200,000	200,000	200,000
Exercise price | $ / shares				$ 0.80
Non cash issue costs allocated to common stock						123,810	123,810
Warrants exercise price | $ / shares				$ 0.786
Warrants expiration date				Mar. 6, 2018	Mar. 6, 2018
Number of warrants of exercised				5,050,000
Broker Warrants [Member]
Stockholders Equity Notes [Textual]
Number of warrants exercisable						8,000	8,000
Number of broker warrants				92,000	92,000	5,000	5,000
Exercise price | CAD / shares					CAD 0.50
Net proceeds from exercise of warrants						$ 3,660	CAD 4,000
Investor Warrants [Member]
Stockholders Equity Notes [Textual]
Exercise price | $ / shares				$ 1.76
Warrants expiration date				Sep. 12, 2018	Sep. 12, 2018
Number of warrants of exercised				277,313
Number of units issued | WarrantsUnit				13,125,002	13,125,002
Unit offering price | $ / shares				$ 0.80
Dividend Warrants [Member]
Stockholders Equity Notes [Textual]
Exercise price | $ / shares				$ 1.25
Warrants expiration date				Jan. 24, 2018	Jan. 24, 2018
Investor Warrants One [Member]
Stockholders Equity Notes [Textual]
Number of warrants of exercised				5,638,285
Unit offering price | $ / shares				$ 0.65

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014
Related Party Transactions (Textuals)
Aggregate amount owing to officers and directors for fees and expenses	$ 90,820	$ 54,960
Valent Technologies, LLC [Member]
Related Party Transactions (Textuals)
Preferred stock, shares issued			278,530
Officer and Director [Member] | Consulting Agreement [Member]
Related Party Transactions (Textuals)
Cash compensation to officers	505,000	425,845
Aggregate amount owing to officers and directors for fees and expenses	90,820
Director fees recognized	$ 119,417	$ 77,833

Current and Future Income Tax48

Current and Future Income Taxes (Details)	Jun. 30, 2015USD ($)
2,029
Schedule of taxable income
Tax credit carryforward, amount	$ 65,450
2,030
Schedule of taxable income
Tax credit carryforward, amount	1,043,923
2,031
Schedule of taxable income
Tax credit carryforward, amount	1,132,631
2,033
Schedule of taxable income
Tax credit carryforward, amount	3,913,138
2,034
Schedule of taxable income
Tax credit carryforward, amount	5,417,455
2,035
Schedule of taxable income
Tax credit carryforward, amount	$ 2,843,797

Current and Future Income Tax49

Current and Future Income Taxes (Details 1) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Components of future tax assets
Non-capital losses carried forward	$ 4,342,685	$ 2,686,530
Financing costs	10,565	7,737
Scientific research and development	183,913	144,235
Gross future tax assets	4,537,163	2,838,502
Valuation allowance	$ (4,537,163)	$ (2,838,502)
Net future tax assets

Current and Future Income Tax50

Current and Future Income Taxes (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax recovery at statutory income tax rates	$ (1,630,650)	$ (989,430)
Permanent differences	(49,820)	110,113
Effect of rate differentials between jurisdictions	327,485	149,219
Other	(4,783)	(8,713)
Change in valuation allowance	$ 1,357,768	$ 738,811
Income tax expense benefit

Current and Future Income Tax51

Current and Future Income Taxes (Details Textual)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Current and Future Income Taxes (Textuals)
Statutory income tax rate	34.00%	34.00%

Commitments and contingencies (

Commitments and contingencies (Details)	May. 27, 2015USD ($)	May. 27, 2015CAD	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
Commitments and contingencies (Textual)
Monthly lease rent for office space	$ 3,082	CAD 3,850
Rent expense			$ 29,429	$ 23,850
Term of free office rent			1 year

Financial Risk Management (Deta

Financial Risk Management (Details) - Foreign Exchange Risk [Member] - CAD	Jun. 30, 2015	Jun. 30, 2014
Concentration Risk [Line Items]
Trade payables	CAD 201,169	CAD 136,825
Cash	CAD 88,205	CAD 65,513

Financial Risk Management (De54

Financial Risk Management (Details 1) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Financial Risk Management [Abstract]
Cash and cash equivalents	$ 1,754,433	$ 4,759,711	$ 6,282,992
Insured amount	70,618
Non-insured amount	$ 1,683,815

Financial Risk Management (De55

Financial Risk Management (Details Textual) - Jun. 30, 2015 - USD ($)	Total
Interest Rate Risk [Member]
Financial risk management (Textual)
Financial risk, interest rate fluctuation benchmark, percentage	10.00%
Financial risk, short-term investments	$ 70,618
Credit Risk [Member]
Financial risk management (Textual)
Credit risk, financial instrument maximum exposure	25,831
Liquidity Risk [Member]
Financial risk management (Textual)
Financial risk, financial instrument maximum exposure	853,084
Foreign Exchange Risk [Member]
Financial risk management (Textual)
Financial risk, accounts payable and accrued liabilities and loan payable	$ 217,423
Financial risk, interest rate fluctuation benchmark, percentage	10.00%
Financial risk, financial instrument maximum exposure	$ 21,742

Subsequent Events (Details)

Subsequent Events (Details)	Jul. 15, 2015USD ($)$ / sharesshares	Jan. 31, 2016$ / sharesshares	Dec. 31, 2015shares	Nov. 30, 2015shares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2015CADshares	Jun. 30, 2014USD ($)$ / sharesCAD / sharesshares	Dec. 31, 2013shares	Jun. 30, 2013shares
Subsequent Events (Textuals)
Common stock, Shares issued					39,455,931		35,992,343
Common stock, Par value | $ / shares					$ 0.001		$ 0.001
Net proceeds from exercise of warrants | $					$ 1,404,177
Warrants exercise price | CAD / shares							$ 0.50
Warrants outstanding					5,550,000		5,987,000		6,200,000
Deferred costs | $					$ 550,119
Stock options [Member]
Subsequent Events (Textuals)
Forfeited					(72,214)	(72,214)	(52,786)
Warrants for services [Member]
Subsequent Events (Textuals)
Net proceeds from exercise of warrants					$ 138,000	CAD 172,500
Number of warrants issued					345,000	345,000		300,000
Warrants [Member]
Subsequent Events (Textuals)
Warrants outstanding					13,472,870
Subsequent Event [Member]
Subsequent Events (Textuals)
Common stock, Shares issued	4,277,667
Common stock, Par value | $ / shares	$ 0.60
Warrants exercise price | $ / shares	$ 0.786
Warrants outstanding	4,372,863
Subsequent Event [Member] | Stock options [Member]
Subsequent Events (Textuals)
Forfeited					50,000	50,000
Stock options exercisable price | $ / shares					$ 1.05
Subsequent Event [Member] | Warrants for services [Member]
Subsequent Events (Textuals)
Number of warrants issued					60,000	60,000
Warrants vested		20,000	20,000	20,000
Warrants exercise price | $ / shares		$ 0.75
Warrants expiration date		Jul. 15, 2020
Subsequent Event [Member] | Placement Agent [Member]
Subsequent Events (Textuals)
Number of warrants issued	56,345
Warrants exercise price | $ / shares	$ 0.75
Warrants expiration date	Jul. 15, 2020
Warrants expiration term	5 years
Percentage of agent fee of warrant	7.00%
Percentage of warrant sold	5.00%
Cash commission | $	$ 80,575
Subsequent Event [Member] | Warrants [Member]
Subsequent Events (Textuals)
Common stock, Par value | $ / shares	$ 0.001
Net proceeds from exercise of warrants | $	$ 2,566,660
Number of warrants issued	4,277,667
Warrants exercise price | $ / shares	$ 0.75
Warrants expiration date	Jul. 31, 2020
Warrants expiration term	5 years
Deferred costs | $	$ 565,000
Carrying amount of deferred costs | $	$ 1,921,085